PreludeTherapeutics (PRLD) Upgradedby MorganStanley to Overweight

PreludeTherapeutics} stock has undergone multiple analysts rating changes in the recent past.  PreludeTherapeutics Upgradedby MorganStanley on 10/8/2021. In a note to investors, the firm issued a new rating of Overweight. The analysts previously had rating of EqualWeight.

View More PreludeTherapeutics (PRLD) Upgradedby MorganStanley to Overweight